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A B S T R A C T
Folic acid (FA) may have a role in the prevention of pregnancy complications. However, the efﬁcacy of FA
supplementation in reducing the risk of preterm birth (PTB) is still unclear. The aim of this systematic
review with meta-analysis was to evaluate the efﬁcacy of folic acid supplementation during pregnancy
to prevent preterm birth (PTB). The research protocol was designed a priori, deﬁning methods for
searching the literature in electronic databases, including and examining articles, and extracting and
analyzing data. We included all randomized trials (RCTs) of asymptomatic singleton gestations without
prior PTB who were randomized to prophylactic treatment with either FA supplementation or control
(placebo or no treatment). The primary outcome was the incidence of PTB <37 weeks. Five randomized
trials including 5,332 asymptomatic singleton gestations without prior PTB were included in the
analysis. Women who received FA supplementation had a similar rate of PTB <37 weeks (22.6% vs 22.9%;
RR 0.99, 95% CI 0.821.18), PTB < 34 weeks (7.1% vs 8.7%; RR 0.77, 95% CI 0.551.09) and of preterm
premature rupture of membranes (2.4% vs 2.9%; RR 0.81, 95% CI 0.441.50) compared with control
group. Regarding neonatal outcome we found no signiﬁcant differences in birth weight (mean difference
85.58 g, 95% CI -55.17226.34), low birth weight (21.0% vs 15.1%; RR 0.79, 95% CI 0.49 to 1.28) and
perinatal death (2.9% vs 2.4%; RR 0.90, 95% CI 0.601.34). In summary, FA supplementation during
pregnancy does not prevent PTB <37 weeks. Daily FA supplementation remains the most important
intervention to reduce the risk of neural tube defects.
 2016 Elsevier Ireland Ltd. All rights reserved.
Contents lists available at ScienceDirect
European Journal of Obstetrics & Gynecology and
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Preterm birth (PTB) remains the number one cause of perinatal
mortality in many countries, including the US [1]. Prior PTB is one
of the most important risk factors for PTB; however, most of these
PTBs occur in women without a prior PTB [2].* Corresponding author at: Department of Obstetrics and Gynecology, Division of
Maternal-Fetal Medicine, Thomas Jefferson University, 833 Chestnut Street, First
Floor, Philadelphia, PA 19107, USA. Tel.: +1 215 955 7996; fax: +1 215 503 6619.
E-mail address: vincenzo.berghella@jefferson.edu (V. Berghella).
http://dx.doi.org/10.1016/j.ejogrb.2016.01.042
0301-2115/ 2016 Elsevier Ireland Ltd. All rights reserved.Folic acid (FA) is a water-soluble vitamin of the B group.
Data from observational studies showed that FA, which is
commonly used to prevent neural tube defects (NTDs) [3],
may have a role in the prevention of pregnancy complications
such as PTB, small for gestational age, preeclampsia and may
lead to prolongation of pregnancy [4–7], However, the efﬁcacy
of FA supplementation in reducing the risk of PTB is still
unclear [4–33].
The aim of this meta-analysis was to evaluate the efﬁcacy of FA
in decreasing the incidence of PTB in asymptomatic singleton
gestations without prior PTB.
Fig. 1. Flow diagram of studies identiﬁed in the systematic review.
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The research protocol was designed a priori, deﬁning methods for
searching the literature, including and examining articles, and
extracting and analyzing data. Searches were performed in MED-
LINE, Scopus, ClinicalTrials.gov, the PROSPERO International Pro-
spective Register of Systematic Reviews, EMBASE, Scielo and the
Cochrane Central Register of Controlled Trials with the use of a
combination of keywords and text words related to ‘‘micronutrients
supplementation,’’ ‘‘folic acid,’’ ‘‘pregnancy,’’ ‘‘folate’’ and ‘‘preterm
birth’’ from inception of each database to October 2015. No
restrictions for language or geographic location were applied.
We included all randomized trials (RCTs) of asymptomatic
singleton gestations who were randomized to prophylactic
treatment with either FA supplementation or control (either
placebo or no treatment). Only trials on singleton gestations
without prior PTB were included. Exclusion criteria included quasi-
randomized trials (i.e. trials in which allocation was done on the
basis of a pseudo-random sequence, e.g. odd/even hospital number
or date of birth, alternation); trials in women with multiple
gestations; prior PTB; FA given also to controls; trials with only
biochemical outcomes available; and trials evaluating other
micronutrient supplementation in addition to FA.
Before data extraction, the review was registered with the
PROSPERO International Prospective Register of Systematic
Reviews (registration No.: CRD42014013874). The meta-analysis
was performed following the Preferred Reporting Item for
Systematic Reviews and Meta-analyses (PRISMA) statement [34].
Data abstraction was completed by two independent investi-
gators (GS, VB). Each investigator independently abstracted data
from each study and analyzed data separately. Differences were
reviewed, and further resolved by common review of the entire
data. All authors were contacted for missing data if possible.
The risk of bias in each included study was assessed by using the
criteria outlined in the Cochrane Handbook for Systematic Reviews
of Interventions [35]. Seven domains related to risk of bias were
assessed in each included trial since there is evidence that
these issues are associated with biased estimates of treatment
effect: 1) random sequence generation; 2) allocation concealment;
3) blinding of participants and personnel; 4) blinding of outcome
assessment; 5) incomplete outcome data; 6) selective reporting;
and 7) other bias. Review authors’ judgments were categorized as
‘‘low risk’’, ‘‘high risk’’ or ‘‘unclear risk’’ of bias [35].Risk of bias was
assessed by authors independently (GS, VB). Differences were
resolved by consensus.
All analyses were done using an intention-to-treat approach,
evaluating women according to the treatment group to which they
were randomly allocated in the original trials. The primary outcome
was the incidence of PTB <37 weeks. Secondary outcomes were PTB
<34 weeks, spontaneous PTB (sPTB) <37 weeks, sPTB <34 weeks,
gestational age (GA) at delivery, latency, preterm premature rupture
of membranes (PPROM) and neonatal outcomes including birth
weight, low birth weight (LBW), admission to neonatal intensive
care unit (NICU), neonatal respiratory distress syndrome (RDS),
bronchopulmonary dysplasia (BPD), intraventricular hemorrhage
(IVH), necrotizing enterocolitis (NEC), neonatal sepsis and perinatal
death. We planned subgroup analysis including RCTs with FA
supplementation of more than 1 mg daily.
The data analysis was completed independently by authors (GA,
VB) using Review Manager 5.3 (Copenhagen: The Nordic Cochrane
Centre, Cochrane Collaboration, 2014). The completed analyses
were then compared, and any difference was resolved with review
of the entire data and independent analysis. Statistical heteroge-
neity between studies was assessed using the Higgins I2 statistic. In
case of statistically signiﬁcant heterogeneity (I2  0%), the random
effects model of DerSimonian and Laird was used to obtain thepooled relative risk (RR) estimate, otherwise in case of no
inconsistency in the risk estimates (I2 = 0%) a ﬁxed effect model
was performed [35]. The summary measures were reported as RR
with 95% conﬁdence interval (95% CI). Potential publication biases
were statistically assessed by using Begg’s and Egger’s tests [35]. p-
value <0.05 was considered statistically signiﬁcant.
Results
We initially identiﬁed 26 trials on FA supplementation during
pregnancy [8–33]. No similar systematic reviews were found
during the search process.
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because they were quasi-randomized trial [13,14]; one because
it evaluated the treatment also in twins [15]; two because they
used also other micronutrients [18,19]; 11 because only biochem-
ical outcomes were available [16,17,20–28]; one because it
compared pregnant women with non-pregnant women [29],
and four because they evaluated the same population of other
included studies [30–33]. Five trials (5,332 women), which met
inclusion criteria for this meta-analysis, were analyzed [8–12].
Fig. 1 shows the ﬂow diagram (PRISMA template) of information
through the different phases of the review.
The characteristics of the ﬁve included trials are summarized
in Table 1. Three studies used iron both in treatment and in control
groups. Three studies used FA 5 mg daily as treatment. Of the
5,332 asymptomatic singleton gestations without prior PTB in the
ﬁve included trials, 1,912 (35.9%) were randomized to FA group,
while 3,420 (64.1%) to control group. Publication bias, assessed
statistically by using Begg’s and Egger’s tests, showed no
signiﬁcant bias (p = 0.22 and p = 0.36, respectively). The qualityTable 1
Descriptive data of included trials.
Study location Years Number of patients
at randomization
Interv
Baumslag 19708 South Africa 19681969 128 (65 vs 63) FA 5 m
Fletcher 19719 United Kingdom 19671969 643 (321 vs 322) FA 5 m
Iyengar 197510 India N/A 230 (134 vs 96) FA 0.5
Charles 200511 United Kingdom 19661967 2365 (463 vs 1902) FA 5 m
Christian 200912 Nepal 19982001 1966 (929 vs 1037) FA 0.4
(1000
Total  5332 (1912 vs 3420)  
Data are presented as total number (n intervention vs control); FA: folic acid; mg: milligr
as iron or vitamin A were identical in intervention and control groups.
*Single blind, blinding of outcome assessment; Double blind, blinding of outcome asse
Fig. 2. Assessment of risk of bias. (a) Summary of risk of bias for each trial; Plus sign: low r
of bias graph about each risk of bias item presented as percentages across all includedof RCTs included in our meta-analysis was assessed by Cochrane
Collaboration’s tool (Fig. 2). Three studies were double blind. None
of the included studies had high risk of bias in ‘‘reporting bias’’ and
‘‘attrition bias’’.
The mean of GA at randomization was about 18 weeks in both
groups. We found no differences in GA at delivery (mean difference
0.10 days, 95% CI -0.050.25) and in latency (mean difference -0.40,
95% CI -0.870.19) between the two groups. Women who received
FA supplementation had a similar rate of PTB <37 weeks (22.6% vs
22.9%; RR 0.99, 95% CI 0.821.18; one study; Fig. 3), PTB <34 weeks
(7.1% vs 8.7%; RR 0.77, 95% CI 0.551.09; one study) and of PPROM
(2.4% vs 2.9%; RR 0.81, 95% CI 0.441.50; one study) compared with
control group. Regarding neonatal outcome we found no signiﬁcant
differences in birth weight (mean difference 85.58 g, 95% CI -
55.17226.34; ﬁve studies), LBW (21.0% vs 15.1%; RR 0.79, 95% CI
0.491.28; four studies) and perinatal death (2.9% vs 2.4%; RR 0.90,
95% CI 0.601.34; two studies; Fig. 4) (Table 2). No data were
available about sPTB <37 weeks, sPTB <34 weeks, NICU, RDS, BPD,
IVH, NEC and neonatal sepsis. We also found no signiﬁcantention Control Blinding* Primary
outcome
g daily and 200 mg iron 200 mg iron only Single blind Rate of LBW
g daily and 200 mg iron 200 mg iron only Double blind Biochemical
outcomes
 mg daily and 60 mg iron 60 mg iron only Double blind Birth weight
g daily Placebo Double blind Biochemical
outcomes
 mg daily and Vitamin A
 g retinol equivalents)
Vitamin A (1000 g
retinol
equivalents)
Single blind Preterm birth
 
ams; LBW: low birth weight; N/A: not available. Doses of other micronutrients such
ssment as well as blinding of participants and personnel
isk of bias; minus sign: high risk of bias; question mark: unclear risk of bias. (b) Risk
 studies.
Fig. 3. Forest plot for the risk of preterm birth less than 37 weeks. FA, folic acid; PTB, preterm birth; CI, conﬁdence interval; M-H, Mantel-Haenszel test.
Fig. 4. Forest plot for the risk of perinatal death. FA, folic acid; Death, perinatal death; CI, conﬁdence interval; M-H, Mantel-Haenszel test.
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subgroup analysis (Table 3).
Comment
This meta-analysis of the ﬁve RCTs evaluating the efﬁcacy of FA
supplementation in preventing PTB in 5,332 asymptomatic
singleton gestations without prior PTB shows that FA supplemen-
tation is not associated with prevention of PTB or improved
neonatal outcomes.
Prior evidence from observational studies showed that, compared
with standard low-dose supplementation, additional folic acid may
prolong gestation, especially if started preconception [4–7]. Biologi-
cally, the authors point to anti-inﬂammatory mechanism [4,7]. There
are several hypotheses that could link FA and prevention of PTB.Table 2
Primary and secondary outcomes.
GA at
randomization
mean (weeks)
GA at
delivery mean
(weeks)
Latency
mean
(days)
PTB < 37
weeks
Baumslag 19708 26 vs 26 N/A N/A N/A 
Fletcher 19719 N/A N/A N/A N/A 
Iyengar 197510 N/A N/A N/A N/A 
Charles 200511 18 vs 18 40 vs 40 158 vs 158 N/A 
Christian 200912 11 vs 11 38 vs 38 190 vs 191 175/776
(22.6%)
vs 201/878
(22.9%)
Total 18 vs 18 39 vs 39 160 vs 161 175/776
(22.6%)
vs 201/878
(22.9%)
Mean difference
(95% CI) or RR
(95% CI)
0.11 weeks
(95% CI -0.12
to 0.30)
0.10 days
(95%
CI -0.050.25)
-0.40 days
(95% CI
-0.870.19)
0.99 (95%
CI 0.821.18)
Data are presented as number intervention vs number control or as total number (n inter
PPROM: preterm premature rupture of membranes; N/A: not available; RR: risk ratio; CI:
delivery outcomes were referred to live-born onlyFirst, periconception FA supplementation may inﬂuence early
placentation processes and placental development regulating the
secretion of matrix metalloproteinases [36]. Second, micronutrient
status at the time of implantation and homocysteine levels could
have a role in inﬂammation [37]; in fact early PTB is often caused by
intrauterine infection and inﬂammation [38]. Furthermore, an
experimental study on mice showed that FA supplementation
during pregnancy prevents PTB, fetal death and intrauterine growth
restriction by an anti-inﬂammatory mechanism [39].
Given that FA is recommended for all women during pregnancy
[3], focusing on whether the use of higher dose of FA leads to further
improved outcomes such as PTB prevention would be helpful.
However, we found no RCTs evaluating the efﬁcacy of high-dose
compared with low-dose FA; two RCTs are currently ongoing
[40,41]. However, even in our subgroup analysis, high-dose FAPTB < 34
weeks
PPROM Birth Weight,
mean (grams)
LBW Perinatal
death
N/A N/A 1547 vs 1520 4/65 (6.2%)
vs 19/63
(30.2%)
N/A
N/A N/A 3330 vs 3330 24/321 (7.5%)
vs 16/322
(5.0%)
N/A
N/A N/A 2890 vs 2650 N/A N/A
N/A N/A 3319 vs 3299 20/459 (4.4%)
vs 115/1890
(6.1%)
8/459 (1.7%)
vs 25/1890
(1.3%)
52/776 (7.1%)
vs 76/878
(8.7%)
17/715
(2.4%)
vs 24/822
(2.9%)
2587 vs 2587 262/628
(41.7%)
vs 297/685
(43.4%)
28/777 (3.6%)
vs 40/876
(4.6%)
52/776 (7.1%)
vs 76/878
(8.7%)
17/715
(2.4%)
vs 24/822
(2.9%)
2842 vs 2796 310/1473
(21.0%)
vs 447/2960
(15.1%)
36/1236
(2.9%)
vs 65/2766
(2.4%)
0.75 (95%
CI 0.531.04)
0.81 (95% CI
0.44 to 1.50)
85.58 grams
(95% CI
-55.17226.34)
0.79 (95%
CI 0.491.28)
0.92 (95%
CI 0.581.46)
vention vs control); GA: gestational age; PTB: preterm birth; LBW: low birth weight;
 conﬁdence interval; RCTs: randomized controlled trials; FA: folic acid. Neonatal and
Table 3
Primary and secondary outcomes in subgroup analysis including trials with folic acid supplementation of  1 mg daily.
GA at
randomization
mean (weeks)
GA at
delivery mean
(weeks)
Latency
mean (days)
PTB < 37
weeks
Birth Weight,
mean (grams)
LBW Perinatal death
Baumslag 19708 26 vs 26 N/A N/A N/A 1547 vs 1520 4/65 vs 19/63 N/A
Fletcher 19719 N/A N/A N/A N/A 3330 vs 3330 24/321 vs
16/322
N/A
Charles 200511 18 vs 18 40 vs 40 158 vs 158 N/A 3319 vs 3299 20/459 vs 115/1890 8/459 vs
25/1890
Total 21 vs 21 40 vs 40 158 vs 158 N/A 2433 vs 2409 48/845 (5.7%) vs
150/2275 (6.6%)
8/459 (1.7%) vs
25/1890 (1.3%)
RR (95% CI) Mean
difference 0.50
week (95% CI
-0.520.30)
Mean
difference 0.10
days (95%
CI -0.050.25)
Mean
difference -0.70
days (-0.800.60)
N/A Mean
difference 81.29
grams (95% CI
-57.24219.83)
0.66 (95%
CI 0.271.63)
1.32 (95%
CI 0.602.90)
Data are presented as number intervention vs number control or as total number (n intervention vs control); GA: gestational age; PTB: preterm birth; LBW: low birth weight;
PPROM: premature rupture of membranes; N/A: not available; RR: relative Risk; CI: conﬁdence interval; RCTs: randomized-controlled trials; FA: folic acid. Neonatal
outcomes were referred to alive-born only
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compared with control, but data were limited.
Another meta-analysis has evaluated the efﬁcacy of FA in
prevention of PTB. However, this meta-analysis did not exclude
RCTs with FA as control, RCTs with multiple gestations, RCTs on
women with prior PTB, and RCTs evaluating also other micro-
nutrients. This review found no conclusive beneﬁt of FA
supplementation during pregnancy on pregnancy outcomes [42].
One of the strengths of our study is inclusion of RCT data on FA
supplementation during pregnancy in a speciﬁc population, i.e.
asymptomatic singleton gestations without prior PTB. This
population represents, in all countries, usually about 90% or more
of the pregnant population. We chose to limit inclusion of studies
to this population as other interventions to prevent PTB have been
shown to have different results in different populations of
pregnant women. For example, progesterone supplementation,
as well as cerclage, has differing effects in populations such as
singleton without prior PTB versus singletons with prior PTB
versus multiple gestations [43–52]. Another strength of our study
is that we planned a subgroup analysis to evaluate just high-dose
FA supplementation. One author provided additional and unpub-
lished data from the original trial [12].
Limitations of our study are inherent to the limitations of the
included RCTs. Most of the included studies were conducted during
the 1970s, so that we found poor compliance with random
allocation. None of the studies randomized FA preconceptionally.
Only one RCT had PTB as primary outcome. The dosage of FA
differed somewhat among studies. While no included study
mentioned that women enrolled had a prior PTB, this characteristic
was not always reported. The study by Christian et al. is the only
one that contributed to the primary outcome, and it was conducted
in Nepal which is a unique low-resource setting. This limitation
raises the question of external generalizability to the current US
population. Preterm delivery rates were very high (about 23%) for
asymptomatic singleton gestations without prior PTB, but were
based on the Christian study alone.
There may be other explanations for the fact that our data show
no association between FA supplementation and prevention of
PTB. First, FA supplementation may have been given too late. The
mean GA at randomization was about 18 weeks, and most other
interventions to prevent PTB, such as progesterone, cerclage or
omega-3, have usually shown efﬁcacy when implemented earlier
[43,44,50,51]. Second, it could be that FA supplementation is only
beneﬁcial in women with FA deﬁciency, a variable which was not
evaluated in the included RCTs. Finally, it could also be that FA
supplementation is truly not effective in preventing PTB.In summary, FA supplementation cannot be currently recom-
mended solely for prevention of PTB. Given the limitations of this
meta-analysis, further large, well-designed, placebo-controlled
trials are needed. Daily FA supplementation remains the most
important intervention to reduce the risk of NTDs.
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